Terremoto Biosciences News and Activities

Acquisition, funding and merger involving Terremoto Biosciences.

• Terremoto Biosciences has just announced a $108 Million fundraising (posted on April 15 2026).

View the org chart displaying its 28 main executives

Most searched biographies at Terremoto Biosciences

• Charles Baum, Chief Executive Officer
• Peter Thompson, Chairman of the Board
• Daniel O'Connell, Director

Popular executive movements at Terremoto Biosciences

• Cora Versaggi, Senior Vice President, Human Resources, has left the company  (posted on June 24 2026).
• Jordan Carelli, Director, Biology, has left the company  (posted on June 23 2026).
• Adam Schayowitz, Director, has left the company  (posted on April 26 2026).

Create your alert
to follow the executive moves at Terremoto Biosciences.

Terremoto Biosciences has 2,424 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• The new name of EG 427 is Cyllene Therapeutics. (posted on July 10 2026).
• Opthea will change its company name to Ceryvyn Therapeutics on Jul 9, 2026. (posted on July 9 2026).
• Tissium has just announced a $60 Million fundraising (posted on July 8 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by Terremoto Biosciences

• Terremoto Biosciences Granted FDA Fast Track Designation for TER-2013, an AKT1-Selective Small Molecule Inhibitor for Breast Cancer | Terremoto
• Terremoto Biosciences Closes $108 Million Series C Financing to Advance Selective AKT1-Inhibitors in Oncology and Hereditary Hemorrhagic Telangiectasia | Terremoto
• Terremoto Biosciences Closes $108 Million Series C Financing to Advance Selective AKT1-Inhibitors in Oncology and Hereditary Hemorrhagic Telangiectasia | Terremoto
• 2026 | Terremoto
• Terremoto Biosciences Appoints James Christensen, Ph.D., as President, Head of Research & Development | Terremoto
• 2025 | Terremoto
• 2024 | Terremoto
• Terremoto Biosciences Appoints Charles Baum, M.D., Ph.D., as Chief Executive Officer | Terremoto
• 2023 | Terremoto
• Terremoto Biosciences Closes $175 Million Series B Financing | Terremoto
• View more press releases Close

Social media about Terremoto Biosciences

• Terremoto Biosciences on Wikipedia, Google News & Yahoo Finance
• Terremoto Biosciences on LinkedIn, X (Twitter) & YouTube